Moksifloksacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moksifloksacin Kabi, is a fluoroquinolone antibiotic presented as an injection for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH USA supplies Moksifloksacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moksifloksacin Kabi is a fluoroquinolone used for severe bacterial infections affecting various organ systems. - Community‑Acquired Pneumonia: effective treatment of moderate to severe cases caused by susceptible pathogens. - Acute Bacterial Sinusitis: eradicates infection when oral therapy is insufficient. - Acute Exacerbation of Chronic Bronchitis: reduces bacterial load and improves respiratory function. - Skin and Soft Tissue Infections: combats Gram‑negative and Gram‑positive organisms. - Intra‑Abdominal Infections: provides broad‑spectrum coverage for mixed flora. - Complicated Urinary Tract Infections: treats infections caused by resistant strains.

Moksifloksacin Kabi may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Elevated liver enzymes: mild hepatic enzyme rise. - Injection site pain: local discomfort after IV administration. - Rash: non‑specific skin eruption.

Serious or Rare Side Effects: - Tendon rupture: especially in older patients or those on corticosteroids. - QT interval prolongation: may precipitate cardiac arrhythmias. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: severe intestinal infection. - Hepatotoxicity: marked liver injury. - Peripheral neuropathy: sensory disturbances.

Before using Moksifloksacin Kabi, clinicians should consider several safety aspects. - Renal impairment: adjust therapy in patients with reduced kidney function. - Hepatic disease: monitor liver function tests during treatment. - Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances. - Concomitant corticosteroids: increase vigilance for tendon disorders. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moksifloksacin Kabi can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of the drug. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of central nervous system stimulation. - Cyclosporine: may raise cyclosporine concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: possible increase in plasma levels, watch for toxicity. - Corticosteroids: heightened risk of tendon rupture, monitor musculoskeletal symptoms.